Multiple myeloma (MM) is a hematological malignancies with plasma cell malignant proliferation, which inhibits the proliferation of normal plasma cells and the secretion of immunoglobulin(Ig) by secreting a large number of Ig and its fragments with defective functions, thus causing injury to relevant organs or tissues. Isatuximab-irfc (sarclisa) is a novel synthetic monoclonal antibody that chimeric with IgG1, which can bind to the CD38 receptor on MM cells and induce MM cell apoptosis through various mechanisms.Isetuximab-irfc is currently used for the treatment of relapsed/refractory MM (RRMM). This review elaborates on the advances in the mechanisms, clinical efficacy and adverse reactions of isatuximab-irfc in the treatment of MM.
